Abstract:In this study, we have investigated 6 novel influenza‐derived peptides predicted to be restricted to the understudied HLA‐B*18:01 molecule. We identified that 3/6 of the novel peptides were immunogenic in samples from several donors and restricted to HLA‐B*18:01 as predicted and were further characterised. Objectives Seasonal influenza viruses cause roughly 650 000 deaths annually despite available vaccines. CD8+ T cells typically recognise influenza‐derived peptides from internal structural and non‐structural influenza proteins and are an attractive avenue for future vaccine design as they could reduce the severity of disease following infection with diverse influenza strains. CD8+ T cells recognise peptides presented by the highly polymorphic Human Leukocyte Antigens class I molecules (HLA‐I). Each HLA‐I variant has distinct peptide binding preferences, representing a significant obstacle for designing vaccines that elicit CD8+ T cell responses across broad populations. Consequently, the rational design of a CD8+ T cell‐mediated vaccine would require the identification of highly immunogenic peptides restricted to a range of different HLA molecules. Methods Here, we assessed the immunogenicity of six recently published novel influenza‐derived peptides identified by mass‐spectrometry and predicted to bind to the prevalent HLA‐B*18:01 molecule. Results Using CD8+ T cell activation assays and protein biochemistry, we showed that 3/6 of the novel peptides were immunogenic in several HLA‐B*18:01+ individuals and confirmed their HLA‐B*18:01 restriction. We subsequently compared CD8+ T cell responses towards the previously identified highly immunogenic HLA‐B*18:01‐restricted NP219 peptide. Using X‐ray crystallography, we solved the first crystal structures of HLA‐B*18:01 presenting immunogenic influenza‐derived peptides. Finally, we dissected the first TCR repertoires specific for HLA‐B*18:01 restricted pathogen‐derived peptides, identifying private and restricted repertoires against each of the four peptides. Conclusion Overall the characterisation of these novel immunogenic peptides provides additional HLA‐B*18:01‐restricted vaccine targets derived from the Matrix protein 1 and potentially the non‐structural protein and the RNA polymerase catalytic subunit of influenza viruses.

Proteome-guided search for influenza A B-cell epitopes

In-depth phylodynamics, evolutionary analysis and in silico predictions of universal epitopes of Influenza A subtypes and Influenza B viruses

Large-Scale Analysis of B-Cell Epitopes on Influenza Virus Hemagglutinin - Implications for Cross-Reactivity of Neutralizing Antibodies

Fine-epitope Mapping of an Antibody That Binds the Ectodomain of Influenza Matrix Protein 2

Identification and Analysis of B Cell Epitopes of Hemagglutinin of H1N1 Influenza Virus.

The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection.

Identification and relative abundance of naturally presented and cross-reactive influenza A virus MHC class I-restricted T cell epitopes

Identification of a universal antigen epitope of influenza A virus using peptide microarray

Immunization with High Epitope Density of M2e Derived from 2009 Pandemic H1n1 Elicits Protective Immunity in Mice

Screening and identification of linear B-cell epitopes on structural proteins of African Swine Fever Virus

Quantitative Prediction of Linear B-Cell Epitopes

Universal antibody targeting the highly conserved fusion peptide provides cross-protection in mice

Identification and In Silico Characterization of a Conserved Peptide on Influenza Hemagglutinin Protein: A New Potential Antigen for Universal Influenza Vaccine Development

Vaccination with M2e-based multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice

Characterisation of novel influenza‐derived HLA‐B*18:01‐restricted epitopes

In silico design of a broad-spectrum multiepitope vaccine against influenza virus

Monoclonal Antibodies Recognizing EVETPIRN Epitope of Influenza A Virus M2 Protein Could Protect Mice from Lethal Influenza A Virus Challenge

Identification of B-cell epitopes located on the surface in the PB2 protein of the H9N2 subtype avian influenza virus

A linear B-cell epitope close to the furin cleavage site within the S1 domain of SARS-CoV-2 Spike protein discriminates the humoral immune response of nucleic acid- and protein-based vaccine cohorts

A Peptide Microarray Platform Approach for Discovery of Immunodominant Antibody Epitopes

Analysis of the affinity of influenza A virus protein epitopes for swine MHC I by a modified in vitro refolding method indicated cross-reactivity between swine and human MHC I specificities